Everolimus (Afinitor) for diffuse large B-cell lymphoma – maintenance therapy

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Lymphoma is a cancer of the lymphatic system, which is part of the immune system. The lymphatic system contains cells called lymphocytes that fight infections. Diffuse large B-cell lymphoma is the most common type of lymphoma. It can occur at any age but is more common in those over 65 years of age. Everolimus is a new drug for diffuse large B-cell lymphoma taken as a tablet once a day. Some studies have suggested everolimus may be helpful in preventing the cancer from coming back in people whose first treatment with chemotherapy has worked. If everolimus is licensed for use in the UK, it could be a new treatment option for diffuse large B-cell lymphoma that may reduce symptoms of the disease and improve survival.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/everolimus-afinitor-for-diffuse-large-b-cell-lymphoma-maintenance-therapy/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Everolimus; Lymphoma, Large B-Cell, Diffuse; Sirolimus; Maintenance

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000631

Date abstract record published
19/04/2016